Listen
OZEMPIC (semaglutide) - 2 diabetes
Reason for request
Summary of opinion
Favourable opinion for reimbursement only for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:
- as dual therapy with metformin,
- as triple therapy with metformin and a sulphonylurea,
- as triple therapy with metformin and basal insulin.
No clinical added value of the new forms compared to the forms already available.
Clinical Benefit
| Moderate |
The clinical benefit of OZEMPIC (semaglutide) is moderate only “for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:
|
| Insufficient |
The clinical benefit of OZEMPIC (semaglutide) is moderate only “for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise insufficient to justify public funding in the other MA situations. |
Clinical Added Value
| no clinical added value |
These medicinal products are range supplements that provide no clinical added value (CAV V) compared to the forms already listed. |
